ANRO — Alto Neuroscience, Inc.
—
NYSE ·
Health Care ·
Pharmaceuticals ·
CIK 1999480 ·
Last close
$21.47
Market Cap
$753.47M
52W High
$28.44
52W Low
$17.90
ADV30
346,437
Next earnings
2026-08-12
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 0 | — | -27,138,000 | -26,237,000 | 276,259,000 | 263,762,000 | 32,890,000 |
| Dec 2025 | 0 | — | -17,055,000 | -16,182,000 | 184,689,000 | 176,484,000 | 33,547,000 |
| Sep 2025 | 0 | — | -14,951,000 | -14,181,000 | 147,006,000 | 137,816,000 | 35,449,000 |
| Jun 2025 | 0 | — | -18,682,000 | -17,706,000 | 157,877,000 | 147,585,000 | 34,465,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-62,304,000
Investing CF
$-556,000
Financing CF
$165,892,000
CapEx
$-2,091,000
Dividends Paid
—
Buybacks
$-4,775,000
EPS Diluted TTM
$-2.53
As of
2026-06-07
Balance + Analyst (yfinance extras)
Retained Earnings
$-227,871,000
Inventory
—
Receivables
$0
ST Investments
—
EBIT TTM
$-71,890,000
Pretax Income TTM
$-74,306,000
Interest Exp TTM
$2,416,000
Analysts
11
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -66,364,000 | -63,238,000 | 184,689,000 | 33,547,000 | — | -51,769,000 |
| Dec 2024 | 0 | -68,610,000 | -61,431,000 | 177,542,000 | 26,082,000 | — | -47,424,000 |
| Dec 2023 | 0 | -37,809,000 | -36,305,000 | 86,628,000 | 158,300,000 | — | -33,448,000 |
| Dec 2022 | 0 | -27,455,000 | -27,710,000 | 50,854,000 | 89,260,000 | — | -20,394,000 |
TTM Snapshot
Revenues TTM
$3,214,000
NetIncome TTM
$-25,924,000
OpCashFlow TTM
$0
Assets (Latest)
$177,542,000
Forward EPS
$-3.43
Max Pain — expiry 2026-07-17 (volume-derived — Yahoo OI feed degraded)
max pain strike: $30.00 · spot: $21.17 · call volume: 50 · put volume: 105
Expected Move to 2026-07-17:
±$7.37
(34.81%) —
implied range
$13.80 –
$28.54
· ATM straddle on $20.00 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| ZVRA | ZEVRA THERAPEUTICS, INC. | $747.81M | $12.65 | — |
| XOMA | XOMA Royalty Corp | $738.79M | $41.79 | — |
| GERN | GERON CORP | $737.75M | $1.15 | — |
| CYRX | Cryoport, Inc. | $736.88M | $14.62 | — |
| ANNX | Annexon, Inc. | $771.70M | $4.71 | — |
News headlines (Yahoo Finance, 1h cache)
Alto Neuroscience Highlights Nature Medicine Publication Demonstrating Significant Effects of Pramipexole on Anhedonia
2026-06-15 12:03 · Yahoo
Alto Neuroscience Appoints Karuna Therapeutics Founder Andrew Miller, Ph.D. to Board of Directors
2026-05-28 12:03 · Yahoo
Alpha Wave Global Initiates COPT Defense Properties Position, According to Recent SEC Filing
2026-05-27 05:19 · Yahoo
Alto Neuroscience CEO Amit Etkin, M.D., Ph.D. Receives Columbia University Transformational Research Award
2026-05-15 12:27 · Yahoo
Alto Neuroscience Reports First Quarter 2026 Financial Results and Recent Business Highlights
2026-05-13 11:03 · Yahoo
Alto Neuroscience Announces Participation in Upcoming Investor Conferences
2026-05-11 20:05 · Yahoo
Alto Neuroscience Presents Phase 2a Data for ALTO-207 in Major Depressive Disorder at SOBP Annual Meeting
2026-05-04 12:03 · Yahoo
Alto Neuroscience Initiates Phase 2b Trial of ALTO-207 in Treatment-Resistant Depression
2026-04-21 12:03 · Yahoo
Top 1% Alto Neuroscience Plummets On Its Shocking Schizophrenia Miss
2026-04-02 20:10 · Yahoo
Sector Update: Health Care Stocks Softer Late Afternoon
2026-04-02 19:57 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.